Navigation Links
Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
Date:1/19/2009

BASEL, Switzerland, January 19 /PRNewswire-FirstCall/ --

- Tamiflu Remains Fully Effective Against 94 Percent of Circulating Influenza Viruses in Europe

Latest surveillance data coming through the European Centre for Disease Prevention and Control (ECDC) from virologists and clinicians indicates that the influenza A(H3N2) virus is the predominant strain in Europe so far this season. Based on the data published by ECDC Roche confirms that the oral antiviral Tamiflu (oseltamivir) is fully active against influenza A(H3N2) and influenza B, which currently comprise 94 percent of circulating viruses in Europe this year.(1)

Tamiflu resistance reported in the 2008-2009 influenza seasons is confined to H1N1. No resistance has been seen with other circulating seasonal viruses - H3N2 and influenza B.

"Recent media reporting has elevated awareness of the H1N1 seasonal resistance seen this year in the United States and the Far East. However, in Europe the picture is different with H3N2 being the dominant strain so far. The circulating H3N2 viruses, which often cause a more severe illness than H1N1, are sensitive to oseltamivir, which means that oseltamivir will be active against the vast majority of influenza infections in Europe this season, if current trends continue," comments Prof Albert Osterhaus, Head of Virology, Erasmus Medical Centre, Rotterdam. "It is important that doctors understand that oseltamivir remains an effective treatment for patients across Europe."

Vaccines are considered first line in the management of seasonal influenza, however, people who show symptoms or have been in close contact with an infected person may require more immediate intervention, such as Tamiflu, which can rapidly treat and prevent influenza.

European surveillance data

The ECDC reports that in the 2008-2009 season, influenza activity is increasing rapidly acr
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
2. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
3. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
4. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
5. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
6. DaVita Launches Flu Fighter Program in Support of National Influenza Week
7. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
8. A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks
9. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
10. Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
11. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Patent Offering, The patent’s technology pertains to an ... within a body lumen (open space). Known as ... cost, single-use disposable illumination and camera module (housing). ... and the patent approval was received on January 6, ... the lighting and magnification of the endoscope for different ...
(Date:5/21/2015)... VANCOUVER , May 21, 2015 /PRNewswire/ - ... a clinical stage regenerative medicine company focused on ... an upcoming poster presentation at the International Society ... treatment for chronic Achilles tendinosis currently in a ... on May 29 th from 5:30 PM ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has announced ... Insights" report to their offering. Technical ... the Health and Wellness sector and has identified top ... in the year 2015. The research service provides an ... wellness technologies that are anticipated to have the highest ...
(Date:5/20/2015)... The global genotyping market is expected to ... period of 2015 to 2020 to reach $17.0billion in ... discovery and development process and to provide personalized therapy, ... this,heavy investments by key manufacturers to offer advanced and ... growth. Browse 113 market data tables & 37 figures ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... Cardium Therapeutics,(NYSE: CXM ) today reported ... of Medicine showing the long-term outcome of a method ... disorder of the immune system.,The infant children studied had ... arises in infants with a genetic defect that,leaves them ...
... Shares of Common StockAt a Price of $5.00 per ... Group, Inc. (the "Company" or "PharmaNet") (Nasdaq: ... today announced that it has signed a definitive merger ... ("JLL"). Under the terms of the Merger Agreement, JLL ...
... Secondary Endpoints -- CAPACITY 1 Misses Primary Endpoint, Provides ... MAA -BRISBANE, Calif., Feb. 3 InterMune, Inc. (Nasdaq: ... two Phase 3 CAPACITY studies evaluating pirfenidone in patients ... of change in percent predicted Forced Vital Capacity (FVC) ...
Cached Biology Technology:Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 2Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 3Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 4Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 3PharmaNet Development Group Agrees to be Acquired by JLL Partners 4PharmaNet Development Group Agrees to be Acquired by JLL Partners 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 6PharmaNet Development Group Agrees to be Acquired by JLL Partners 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 2InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 3InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 4InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 5InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 6InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 8InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 9InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 10InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 11
(Date:4/27/2015)... , April 27, 2015  For more than four ... show has been the premier worldwide event for the ... is a must-attend event for any local, national, or ... the emerging commercial markets and current applications of unmanned ... of this projected $48 billion industry, and how it ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... neuroscientists at Georgetown University Medical Center found significant differences ... dyslexia to their non-dyslexic control groups, suggesting that the ... sex., Their study, investigating dyslexia in both males and ... of females with and without dyslexia (in children and ...
... of tissue during surgical operations has the potential to ... to conventional sutures and stapling in intestinal surgery, scientists ... gold-based solder, or sealing material, appears in the journal ... colleagues explain that laser tissue welding (LTW) is a ...
... Sydney, Australia -- Researchers from the University of ... is needed to understand how micro-organisms respond to ... in medical and environmental applications. Although nanosilver ... to silver nano-particles can cause other potentially harmful ...
Cached Biology News:Brain anatomy of dyslexia is not the same in men and women, boys and girls 2Bacteria adapt and evade nanosilver's sting -- new study 2
... Hybridization Cassettes facilitate the hybridization of DNA ... standard 25mm x 75mm glass slides. The ... to correct for poor flatness, as is ... its low volume chamber (67uL analytical cavity ...
... reagent is formulated specifically for Alkaline Phosphatase ... levels of activity for both the enzyme ... final dilution. This product has been ... the customer a longer shelf life, resistance ...
... to Lambda Free Light Chain ... chains of human immunoglobulin. ... expressed epitope of lambda chain. Reacts ... free lambda chains but not with ...
... valuable tool for removing SDS detergent from ... in biological samples imparts a negative charge ... enzymatic activity during digestion, and suppresses ion ... mass spectrometry analyses. We recommend that ...
Biology Products: